From Medscape Neurology

Coverage from the

37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2021

October 13 - 15, 2021; Virtual

October 13 - 15, 2021 Virtual

Conference News

Popular News from ECTRIMS 2020

  • Masitinib Impresses in 'Nonactive' Progressive MS Masitinib Impresses in 'Nonactive' Progressive MS The drug, with a completely new mechanism of action for multiple sclerosis, slowed disability in nonactive primary and secondary progressive forms of the disease, where there is no current treatment.
  • High Plasma GFAP Level Predicts Disability in Progressive MS High Plasma GFAP Level Predicts Disability in Progressive MS A high level of glial fibrillary acidic protein (GFAP) in the blood may predict worsening disability in patients with secondary progressive multiple sclerosis (MS), according to investigators.
  • Lower Rituximab Dose as Effective, Safer in MS Lower Rituximab Dose as Effective, Safer in MS Further data suggest that a lower dose of rituximab may offer similar effectiveness with a better safety profile than a higher dose commonly used.

Medscape Neurology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.